Amgen Acquires KAI Pharmaceuticals for $315,000,000

  • Feed Type
  • Date
    4/10/2012
  • Company Name
    KAI Pharmaceuticals
  • Mailing Address
    270 Littlefield Avenue South San Francisco, CA 94080
  • Company Description
    KAI Pharmaceuticals is a biology-based product-driven pharmaceutical company developing a new class of therapeutics targeting cell-signaling enzymes that affect numerous disease pathways. The company is leveraging its leadership position in protein kinase C (PKC), an important and validated family of kinases, to rapidly advance product candidates into human clinical trials.
  • Website
    http://www.kaipharmaceuticals.com
  • Transaction Type
    M&A
  • Transaction Amount
    $315,000,000
  • Transaction Round
  • Proceeds Purposes
  • M&A Terms
    The acquisition will be paid for with all cash.

By posting a comment, you agree to our terms and conditions.